PIK3CD and cancer: The results indicate that, in contrast to taselisib and other pan-inhibitors, MEN1611 displays a greater potency against PI3Kα than PI3Kδ at clinically relevant concentrations, as demonstrated by a higher IC50 ratio between the targeting of p110α- versus p110δ-dependent models (IC50 normal B cells/IC50 T47D cancer cells of 4.89 for MEN1611 versus 0.79 for taselisib).